Cancer in Both Breasts May Not Be Deadlier Than One, Landmark Study Finds

For women who hear the words “you have cancer in both breasts” on the same day, the fear is immediate and visceral: two tumors must surely mean double the danger. A large new study from South Korea challenges that intuition. Researchers at Seoul National University Bundang Hospital have found that synchronous bilateral breast cancer, the simultaneous diagnosis of tumors in both breasts, does not carry a worse prognosis than cancer confined to one breast, provided that the tumors are compared fairly and their biological characteristics are taken into account. The findings, published in BMC Cancer, offer some of the strongest evidence yet that what a breast tumor is made of matters far more than how many breasts it occupies.

The research team, led by Yena Yoon and corresponding author Hee-Chul Shin, assembled one of the largest single-institution cohorts ever used to study this question. Drawing on two decades of records from 2004 to 2023, they identified 383 patients with synchronous bilateral breast cancer and 9,573 patients with unilateral breast cancer, all treated at the same hospital. That scale matters. Earlier studies of bilateral disease have often relied on small numbers of patients, making it difficult to distinguish genuine biological differences from statistical noise, and few have adequately controlled for the fact that women with bilateral tumors tend to differ in age, tumor type, and other baseline features from women with unilateral disease.

To address that problem, the investigators turned to propensity score matching, a statistical technique that has become a workhorse of observational research. In a randomized trial, chance alone determines who receives which condition, balancing known and unknown factors between groups. Observational data lack that built-in fairness, so propensity matching attempts to recreate it mathematically. Each patient’s propensity score summarizes the probability of belonging to one group rather than the other, given a set of measured characteristics such as age, tumor stage, nodal status, and molecular subtype. By matching each bilateral case with four unilateral cases of similar score, the team constructed a comparison cohort of 1,532 unilateral patients against the 383 bilateral patients, in which the two groups were balanced on the measured baseline variables.

The matching process itself revealed something important. Before any statistical adjustment, the bilateral and unilateral tumors were not interchangeable. Synchronous bilateral cancers were more frequently hormone receptor-positive, meaning their cells carried molecular docking sites for estrogen or progesterone that fuel growth and can be blocked with endocrine therapy. They were also more often negative for human epidermal growth factor receptor 2, or HER2, a protein that marks an aggressive but targetable subtype, and they tended to be of lower histological grade, a pathologist’s measure of how abnormal and fast-dividing the tumor cells appear under the microscope. In other words, the bilateral tumors in this cohort were, on average, biologically gentler than the unilateral tumors they were compared against.

That pattern makes biological sense. Many synchronous bilateral cancers are thought to arise in part through a field effect, in which widespread hormonal or genetic influences across both breasts create fertile ground for tumors to develop on both sides at once. Such tumors are often driven by hormone signaling rather than by the high-grade, rapidly proliferating biology seen in HER2-enriched or triple-negative disease. Detecting them has also become easier over the study period, as magnetic resonance imaging and routine screening have grown more sensitive, picking up small second tumors that earlier generations of imaging would have missed. The rising detection rate of bilateral disease, the authors note, has made it increasingly urgent to determine whether it truly represents a more dangerous condition or simply a different one.

To answer that question, the team tracked two endpoints: recurrence-free survival, the length of time patients remain free of any return of their cancer, and overall survival, the ultimate measure of whether the disease proves fatal. Using Kaplan-Meier analysis, a method that estimates survival probabilities over time while accounting for patients who leave the study or are still under observation, they compared the curves for the two groups. Both before and after propensity matching, the curves were statistically indistinguishable. Patients with cancer in both breasts were no more likely to experience a recurrence or to die than patients with comparable cancer in one breast. Cox proportional hazards regression, which estimates how each factor multiplies the hazard of an event over time, confirmed that bilateral laterality itself was not a significant predictor of either outcome.

The study then probed a subtler question: does it matter whether the two tumors in a bilateral case are biologically identical? The researchers split the bilateral group into subtype-concordant pairs, in which both tumors belonged to the same molecular class, and subtype-discordant pairs, in which the two tumors differed. Of the bilateral patients, 200 had concordant pairs and 102 had discordant pairs. Subgroup analysis found no significant survival differences among the unilateral, concordant, and discordant groups. There was, however, a non-significant trend toward reduced overall survival in the subtype-concordant group, a signal the authors are careful to contextualize rather than overinterpret.

That caution is warranted, and the supplementary data explain why. When the 200 concordant patients were stratified by biological subtype, the apparent survival disadvantage concentrated almost entirely in a tiny subgroup of just 12 patients whose paired tumors were both of poor-prognosis biology, either HER2-enriched or triple-negative. Within the concordant subgroup, overall survival differed dramatically between those 12 patients and the 188 patients with paired luminal tumors, with a hazard ratio of 9.52 and a confidence interval well clear of unity. In other words, the trend was not a property of bilateral disease at all, but a reflection of the well-known lethality of aggressive tumor biology, observed in a sample too small to support firm conclusions. The authors explicitly label the finding hypothesis-generating and call for larger cohorts to clarify whether subtype discordance within bilateral disease carries any prognostic weight of its own.

The practical implications reach into the clinic. Treatment for breast cancer is increasingly guided by tumor biology: hormone receptor-positive tumors receive endocrine therapy, HER2-positive tumors receive targeted antibodies, and triple-negative tumors rely on chemotherapy. The new results support that biology-first approach, suggesting that a bilateral diagnosis need not, by itself, trigger more aggressive treatment than a unilateral one of equivalent biological character. Long-term follow-up reinforced the message: when overall survival was tracked over an extended observation period of up to 200 months, the matched curves remained closely aligned and eventually intersected, indicating that the prognostic parity between bilateral and unilateral disease holds well beyond the early years after diagnosis.

Like all retrospective single-institution studies, the analysis has limits. Propensity matching can only balance the variables that are measured, leaving open the possibility of residual confounding by factors such as detailed genetic risk, including inherited mutations in BRCA1 and BRCA2, or by differences in surveillance intensity. The bilateral cohort, though large by the standards of this literature, is still modest in absolute terms, and the discordant subgroup in particular remains small. Yet the study’s scale, its two-decade span, and its rigorous matching design give unusual weight to its central conclusion. For the growing number of women found to have tumors in both breasts, the message is quietly reassuring: two tumors do not automatically mean twice the threat, and the biology of the cancer, not its geography, remains the compass that should guide treatment.

Subject of Research: Comparison of clinicopathological characteristics and survival outcomes between synchronous bilateral and unilateral breast cancer

Article Title: Clinicopathological characteristics of synchronous bilateral breast cancer compared to unilateral breast cancer: a propensity score-matched analysis

Article References: Yoon, Y., Kim, E.-K., Yoon, K.-H., Koh, H. W., Oh, J. H., Kang, J., Jeong, S., Lee, S., Park, S. Y., Seo, S. H., Kim, H., & Shin, H.-C. (2026). Clinicopathological characteristics of synchronous bilateral breast cancer compared to unilateral breast cancer: a propensity score-matched analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16942-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16942-y

Keywords: breast cancer, synchronous bilateral breast cancer, propensity score matching, hormone receptor, HER2, survival analysis, tumor biology, recurrence-free survival, overall survival, molecular subtype, retrospective cohort, BMC Cancer